These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 20641040)

  • 1. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
    Li X; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Grisanti M; Dwyer D; Stouch B; Thway TM; Stolina M; Ominsky MS; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    J Bone Miner Res; 2010 Dec; 25(12):2647-56. PubMed ID: 20641040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X; Niu QT; Warmington KS; Asuncion FJ; Dwyer D; Grisanti M; Han CY; Stolina M; Eschenberg MJ; Kostenuik PJ; Simonet WS; Ominsky MS; Ke HZ
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
    Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
    J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X; Jee WS; Li X; Paszty C; Ke HZ
    Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
    Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
    Liu Y; Rui Y; Cheng TY; Huang S; Xu L; Meng F; Lee WY; Zhang T; Li N; Li C; Ke H; Li G
    Calcif Tissue Int; 2016 Mar; 98(3):263-74. PubMed ID: 26603303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.
    Hamann C; Rauner M; Höhna Y; Bernhardt R; Mettelsiefen J; Goettsch C; Günther KP; Stolina M; Han CY; Asuncion FJ; Ominsky MS; Hofbauer LC
    J Bone Miner Res; 2013 Mar; 28(3):627-38. PubMed ID: 23109114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
    Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
    Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
    J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.
    Ke HZ; Crawford DT; Qi H; Simmons HA; Owen TA; Paralkar VM; Li M; Lu B; Grasser WA; Cameron KO; Lefker BA; DaSilva-Jardine P; Scott DO; Zhang Q; Tian XY; Jee WS; Brown TA; Thompson DD
    J Bone Miner Res; 2006 Apr; 21(4):565-75. PubMed ID: 16598377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.
    Frost M; Andersen T; Gossiel F; Hansen S; Bollerslev J; van Hul W; Eastell R; Kassem M; Brixen K
    J Bone Miner Res; 2011 Aug; 26(8):1721-8. PubMed ID: 21351148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis.
    Chen H; Xu X; Liu M; Zhang W; Ke HZ; Qin A; Tang T; Lu E
    Bone; 2015 Jul; 76():141-8. PubMed ID: 25868799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.
    Tian X; Setterberg RB; Li X; Paszty C; Ke HZ; Jee WS
    Bone; 2010 Sep; 47(3):529-33. PubMed ID: 20561907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.